Aptinyx Appoints Joan W. Miller, M.D. to Board of Directors
May 10 2021 - 7:57AM
Business Wire
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical
company developing transformative therapies for the treatment of
brain and nervous system disorders, today announced the election of
Joan W. Miller, M.D., to the company’s Board of Directors. Dr.
Miller currently serves as the David Glendenning Cogan Professor of
Ophthalmology and Chair of the Department of Ophthalmology at
Harvard Medical School, as well as Chief of Ophthalmology at both
Massachusetts Eye and Ear and Massachusetts General Hospital, and
Ophthalmologist-in-Chief at Brigham and Women’s Hospital.
“We are delighted to welcome Joan to the Aptinyx Board of
Directors,” said Norbert Riedel, Ph.D., chief executive officer of
Aptinyx. “Joan is a highly accomplished physician scientist,
academic executive, and healthcare leader. Her distinguished track
record as a researcher, clinician, and leading authority in the
field of ophthalmology will serve as an invaluable resource to
Aptinyx as we advance new therapeutic candidates for people living
with serious central nervous system disorders.”
Dr. Miller has extensive experience in academic medicine,
clinical trials, and clinical research, including the development
of the first FDA-approved therapies for age-related macular
degeneration (AMD), and is an internationally recognized expert in
the field of retinal diseases. Dr. Miller has authored more than
280 peer-reviewed articles and over 95 book chapters, review
articles, or editorials. Dr. Miller is a member of the National
Academy of Medicine, a Gold Fellow of the Association for Research
in Vision and Ophthalmology (ARVO), and she has served on numerous
Scientific Advisory Boards across the biopharmaceutical industry.
She was the co-recipient of the 2014 António Champalimaud Vision
Award, the highest distinction in ophthalmology and visual science.
Throughout her career, Dr. Miller has been a pioneering figure in
academic leadership, becoming the first female physician to achieve
the rank of Professor of Ophthalmology at Harvard Medical School,
and the first woman to serve as Chair of the Department of
Ophthalmology. Additionally, she was the first woman to receive
both the Mildred Weisenfeld Award for Excellence in Ophthalmology
from ARVO, as well as the Charles L. Schepens Award from American
Academy of Ophthalmology.
“I am pleased to be joining Aptinyx at this exciting juncture in
the company’s pursuit of developing better therapeutic options for
patients with serious neurological disorders,” said Dr. Miller. “I
look forward to working together with the management and fellow
members of the board in advancing these potentially
transformational NMDA receptor modulator candidates to
patients.”
Dr. Miller earned an S.B. in life sciences from the
Massachusetts Institute of Technology and an M.D. cum laude from
Harvard Medical School. She subsequently completed residency
training in ophthalmology followed by a vitreoretinal clinical
fellowship at Massachusetts Eye and Ear, Harvard Medical
School.
About Aptinyx
Aptinyx Inc. is a clinical-stage biopharmaceutical company
focused on the discovery, development, and commercialization of
proprietary synthetic small molecules for the treatment of brain
and nervous system disorders. Aptinyx has a platform for discovery
of novel compounds that work through a unique mechanism to
modulate—rather than block or over-activate—NMDA receptors and
enhance synaptic plasticity, the foundation of neural cell
communication. The company has three product candidates in clinical
development in central nervous system indications, including
chronic pain, post-traumatic stress disorder, and cognitive
impairment. Aptinyx is also advancing additional compounds from its
proprietary discovery platform, which continues to generate a rich
and diverse pipeline of small-molecule NMDA receptor modulators
with the potential to treat an array of neurologic disorders. For
more information, visit www.aptinyx.com or follow Aptinyx on
Twitter @Aptinyx.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the company’s business plans and objectives, including future plans
or expectations for the company’s product candidates, therapeutic
effects of the company’s product candidates, expectations regarding
the design, implementation, timing, the expected impact and
contribution of our board of directors and executives to our
business, and success of its current and planned clinical studies,
and expectations regarding its uses and sufficiency of capital.
Risks that contribute to the uncertain nature of the
forward-looking statements include: the success, cost, and timing
of the company’s product candidate development activities and
planned clinical studies; the company’s ability to execute on its
strategy; positive results from a clinical study may not
necessarily be predictive of the results of future or ongoing
clinical studies; regulatory developments in the United States and
foreign countries; as well as those risks and uncertainties set
forth in the company’s most recent Annual Report on Form 10-K and
subsequent filings with the Securities and Exchange Commission. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Aptinyx undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
Source: Aptinyx Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210510005186/en/
Investor & Media Contact: Nick Smith Aptinyx Inc.
ir@aptinyx.com or corporate@aptinyx.com 847-871-0377
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From Sep 2023 to Sep 2024